Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 10« First...34567...10...Last »

Patch May Boost Repair After Heart Attack, Stanford University Study

A prototype patch could help repair the damage caused by a heart attack, scientists say. The early work, carried out on mice and pigs, reveals the protein-infused patch encourages the growth of healthy cells and leads to less scarring. Scarring can be common after a heart attack, making the heart pump less effectively and sometimes […]

Read More »

Analysis of GSK’s Seroxat antidepressant finds key data was held back

A medical journal criticized British drugmaker GlaxoSmithKline on Thursday for delaying access to key data from a trial of its antidepressant Seroxat that would have shown earlier that it is neither safe or effective in adolescents.   The widely used medicine, known generically as paroxetine, is linked to an increased risk of suicide in young people […]

Read More »

GE executive says no intent to split off healthcare businesses

General Electric Co has no intent to split off any significant parts of its healthcare business, GE’s head of the unit said on Wednesday, and that “all aspects” of the $18 billion division are part of the company’s portfolio. Some analysts and investors over time have raised questions about how smoothly GE’s healthcare business fits […]

Read More »

Aerie Pharmaceuticals’ eye drop succeeds in late-stage study

Drugmaker Aerie Pharmaceuticals Inc said on Wednesday its experimental eye drop met the main goal of a late-stage study, sending its shares up as much as 65 percent in extended trading. The drug, Rhopressa, showed that it was not inferior to a commonly prescribed treatment, timolol, in reducing pressure inside the eye in patients suffering […]

Read More »

Department of Health and Human Services, AstraZeneca to develop antibiotics

The U.S. Department of Health and Human Services (HHS) said on Wednesday it signed a deal with British drugmaker AstraZeneca Plc to develop antibiotics. The federal agency said it will share costs with AstraZeneca to develop a portfolio of drugs to treat illnesses caused by bioterrorism agents and antibiotic-resistant infections. The Biomedical Advanced Research and […]

Read More »

World’s biggest private biotech Intarcia in no rush to list

Intarcia Therapeutics, with an enviable cash pile to fund development of its matchstick-size implantable drug-delivery pump for diabetes, is happy to sit out the current initial public offering (IPO) boom. The Boston-based group clinched a royalty-based financing deal in April valuing the company at $5.5 billion, more than any other unlisted emerging biotechnology business in […]

Read More »

Merck’s once-weekly diabetes drug found effective in study

Merck & Co said its experimental once-weekly diabetes drug was found to be as good as its blockbuster Januvia, which is taken once a day. The late-stage study compared 25 mg of the drug, omarigliptin, to 100 mg of Januvia. Both treatments belong to a family of drugs called DPP-4 inhibitors that help lower blood […]

Read More »

Novo Nordisk A/S’s Victoza Beats Sanofi’s Lixisenatide in Head-to-Head Study, Company Says

STOCKHOLM – Novo Nordisk (NVO) reported today that its type 2 diabetes treatment Victoza in combination with metformin, proved superior in reducing HbA1c than Sanofi’s lixisenatide in combination with metformin.   Novo’s stock jumped slightly this morning to a price of $56.37, up from its opening $55.94 per share. In the head-to-head trial, which surveyed […]

Read More »

Amgen To Acquire Privately Held Dezima Pharma

Strengthens Amgen’s Cardiovascular Portfolio With Late-Stage, Oral CETP Inhibitor   THOUSAND OAKS, Calif. and NAARDEN, Netherlands, Sept. 16, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative […]

Read More »

Intra-Cellular’s schizophrenia drug effective in higher dosage

Intra-Cellular Therapies Inc said a higher dose of its lead drug was found to be effective in reducing the severity of schizophrenia symptoms in a late-stage study, sending its shares up more than 50 percent in premarket trading. Patients treated with 60 mg of the drug, ITI-007, showed improvement over placebo. The 40 mg dosage, […]

Read More »

Nestle enters agreement to develop ulcerative colitis therapy

Nestle is working with Lipid Therapeutics to develop and commercialize a new therapeutic treatment for mild-to-moderate ulcerative colitis, which can causes ulcers, bleeding and pain due to inflammation of the colon, the company said on Wednesday. Nestle Health Science intends to develop an add-on therapy to an existing one that is commonly used but with […]

Read More »

Beyond cancer, Roche pins big hopes on new MS drug

Swiss drugmaker Roche has big ambitions beyond treating cancer, where it is already global market leader, and believes it has a winner in a new multiple sclerosis drug.   While the market for multiple sclerosis (MS) treatments is relatively crowded, Roche thinks its drug ocrelizumab, for which clinical data will be unveiled next month, can […]

Read More »

Former Naurex Team Launches New Spin-Out Company, Aptinyx

EVANSTON, Ill., Sept. 16, 2015 /PRNewswire/ — Aptinyx Inc., a biopharmaceutical company advancing modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging disorders of the brain and nervous system, has launched with the discovery platform and preclinical pipeline spun out of Naurex upon the close of its acquisition by Allergan in August 2015. “As […]

Read More »

Dental supply maker Dentsply to buy Sirona in $5.56 billion deal

Dentsply International Inc (XRAY.O) said on Tuesday it would merge with peer Sirona Dental Systems Inc (SIRO.O) in a $5.56 billion all-stock deal, creating the world’s largest dental equipment maker. The deal will combine Dentsply’s single-use dental supplies, such as paste and sealants, with Sirona’s advanced technology equipment, such as imaging systems and instruments. “There […]

Read More »

Obama nominates Robert Califf as FDA commissioner

President Barack Obama has nominated Dr. Robert Califf, a leading cardiologist and researcher, as the next commissioner of the U.S. Food and Drug Administration, a sprawling agency that oversees everything from food and drugs to tobacco, dietary supplements and cosmetics.   Califf, whose nomination was announced on Tuesday, joined the agency in January as a […]

Read More »

CDC appoints new safety czar to improve handling of dangerous pathogens

The U.S. Centers for Disease Control and Prevention on Tuesday tapped Dr. Stephen Monroe, a longtime lab scientist and agency insider, to oversee the safe handling of dangerous pathogens by more than 2,000 scientists in the agency’s more than 150 labs. Monroe becomes the CDC’s first permanent associate director of lab safety, reporting directly to […]

Read More »

Roche says biotech bubble pushes midsize buys out of reach

The biotechnology sector is in a “bubble”, pushing prices for medium-sized companies with experimental drugs in late-stage development out of reach, the chief executive of drugmaker Roche said on Tuesday.   “I think this bubble will burst at some point,” Severin Schwan told Reuters in an interview during a visit to London. The Swiss company […]

Read More »

Study finds young people on antidepressants more prone to violence

Young people taking antidepressants such as Prozac and Seroxat are significantly more likely to commit violent crimes when they are on the medication, but taking higher doses of the drugs appears to reduce that risk, scientists said on Tuesday.   In research published in the PLoS Medicine journal, the scientists said that while their finding […]

Read More »

Cannabis drug shows promise in treating schizophrenia

An experimental cannabis drug for treating schizophrenia, developed by UK-based GW Pharmaceuticals Plc, was found to be superior to a placebo in a mid-stage trial. The company’s UK-listed shares jumped 12.5 percent, while U.S.-listed shares were up 10 pct. The drug, cannabidiol, was tested in 88 patients with schizophrenia, who had failed to respond to […]

Read More »

Analysts bet Novo’s insulin drug will get U.S. green light

Analysts are confident the U.S. Food and Drug Administration (FDA) will soon approve Novo Nordisk’s new long-lasting insulin drug Tresiba — just as they were before the drug was first rebuffed two years ago. Tresiba is considered as a future blockbuster for the Danish company, the Nordic region’s most valuable, but the U.S. regulator asked […]

Read More »

Page 5 of 10« First...34567...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom